Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Woman throwing punch at punching bag.

Investor Relations

Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics

(As of September 30, 2024)

  • $164M

    TTM Revenue

  • $20M

    TTM Adjusted EBITDA

  • $63M

    Cash balance

    with no debt

  • #1

    OA Pain
    U.S. Market Share

    ~25M

    Injections
    Worldwide

Recent News
Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference
Dec 23, 2024

BEDFORD, Mass. — December 23, 2024 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that Dr. Cheryl Blanchard,...

Anika To Participate in December 2024 Investor Conferences
Nov 22, 2024

BEDFORD, Mass. — November 22, 2024 – Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will...

Anika Reports Third Quarter 2024 Financial Results
Oct 31, 2024

BEDFORD, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results...

All Press Releases

Current Investor Presentation

View PresentationView More
Investor Contacts

Primary IR Contact

  • Matt Hall

    Director, Corporate Development and Investor Relations

    Anika Therapeutics, Inc.

    Phone: (781) 457-9554

    Email: investorrelations@anika.com

  • Transfer Agent

    Equiniti Trust Company LLC

    6201 15th Avenue

    Brooklyn NY 11219

    Phone: (800) 937-5449

Want Alerts? Sign up for alerts and never miss an Investor update!

Subscribe

To Top